PepGen (PEPG) Accumulated Expenses (2021 - 2026)
PepGen (PEPG) posted Accumulated Expenses of $1.4 million for Q1 2026, down 69.33% sequentially from $4.7 million in Q4 2025, and down 90.22% YoY from $14.6 million in Q1 2025.
Analysis
PepGen (PEPG) Accumulated Expenses (2021 - 2026) Analysis & Trends
PepGen has reported Accumulated Expenses for 6 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Accumulated Expenses fell 90.22% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 90.22% YoY) and the FY2025 annual result came in at $4.7 million, up 28.92% from the prior year.
- Accumulated Expenses retreated to $1.4 million in Q1 2026 per PEPG's latest filing, from $4.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $15.2 million in Q2 2022 and troughed at $635000.0 in Q1 2022.
- A 5-year average of $5.7 million and a median of $3.1 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses jumped 1211.94% in 2025, then plunged 90.22% in 2026.
- Over 5 years, Accumulated Expenses stood at $2.4 million in 2022, then dropped by 2.95% to $2.4 million in 2023, then jumped by 52.74% to $3.6 million in 2024, then climbed by 28.92% to $4.7 million in 2025, then plunged by 69.33% to $1.4 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.4 million, $4.7 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68 Mn |
| Mar 31, 2026 | 5.13 Mn |
| Dec 31, 2025 | 8.64 Mn |
| Sep 30, 2025 | 8.71 Mn |
| Jun 30, 2025 | 12.36 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Dec 31, 2024 | 11.85 Mn |
| Sep 30, 2024 | 7.81 Mn |
| Jun 30, 2024 | 11.32 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 13.52 Mn |
| Sep 30, 2023 | 13.98 Mn |
| Jun 30, 2023 | 11.63 Mn |
| Mar 31, 2023 | 12.90 Mn |
| Dec 31, 2022 | 11.91 Mn |
| Sep 30, 2022 | 10.90 Mn |
| Jun 30, 2022 | 15.19 Mn |
| Mar 31, 2022 | 14.23 Mn |
| Dec 31, 2021 | 7.08 Mn |